Synopsis: Gland Pharma shares rose up to 5% after the USFDA approved its Olopatadine Hydrochloride 0.7% ophthalmic solution, expanding its ophthalmic generics portfolio, equivalent to Alcon’s Pataday.
The shares of Pharma Company, specialising in manufacturing generic injectable pharmaceuticals, focusing on complex sterile injectables, oncology, and ophthalmics, offering products in vials, pre-filled syringes, and more, are in focus as it expands its portfolio with a USFDA nod for Olopatadine Eye Drops.
With a market capitalization of Rs. 28,492.98 Crores on Thursday, the shares of Gland Pharma Ltd jumped upto 5.1 percent, reaching a high of Rs. 1795.85 compared to its previous closing price of Rs. 1708.50.
What Happened
Gland Pharma Ltd, engaged in manufacturing generic injectable pharmaceuticals, focusing on complex sterile injectables, oncology, and ophthalmics, offering products in vials, pre-filled syringes, and more, has informed that it has received approval from the United States Food and Drug Administration (USFDA).
The approval is for its Abbreviated New Drug Application for Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC). The product is therapeutically equivalent to Alcon Laboratories’ Pataday Once Daily Relief 0.7% and is used to treat ocular itching caused by allergic conjunctivitis.
Financials & Others
The company’s revenue rose by 5.77 percent from Rs. 1,406 crores to Rs. 1,487 crores in Q2FY25-26. Meanwhile, Net profit rose from Rs. 164 crores to Rs. 184 crores in the same period.
The company demonstrates decent capital efficiency with an ROCE of 11.9 percent and a moderate ROE of 7.81 per cent, indicating reasonable returns on invested and shareholders’ funds. It maintains a strong balance sheet, being almost debt-free with a debt-to-equity ratio of just 0.03, which reduces financial risk.
Additionally, the company has shown consistent shareholder friendliness by maintaining a healthy dividend payout of 28.4 percent, reflecting stable cash flows and prudent capital allocation.
Gland Pharma was established in 1978 in Hyderabad and has grown over the years from a contract manufacturer of small-volume liquid parenteral products to become one of the largest injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets.
It operates primarily under a business-to-business (B2B) model and has an excellent track record in developing, manufacturing, and marketing sterile injectables. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilised vials, dry powders, infusions, oncology, and ophthalmic solutions. It also enjoys the distinction of having pioneered Heparin technology in India.
Gland Pharma’s base business showed steady progress in Q2 FY26, with R&D expenses rising to Rs. 614 million (5.8% of revenue) from Rs. 460 million in Q1 FY26, reflecting continued investment in product development.
During the quarter, the company strengthened its U.S. portfolio by launching seven molecules, including Daptomycin-RTU, Sumatriptan, and a new strength of Colistimethate, enhancing its presence in key injectable segments.
The in-house complex injectable pipeline continues to be a core growth driver, with six products already commercialised and three more awaiting approval, while additional complex products are being steadily added to support long-term growth.
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Gland Pharma jumps 5% after receiving USFDA approval for Olopatadine Eye Drops appeared first on Trade Brains.